Results showed that higher TGFB1 expression levels correlated with lower progression-free survival in the TCGA PRAD dataset as well as a lower OS ratio in TCGA Pan-Cancer (PANCAN) dataset by Kaplan–Meier analysis (Supplemental Fig. S2j, k), which was consistent with our previous findings (Fig. 2i–l). The gene discussed is TGFB1; the disease is prostate adenocarcinoma.